Virax Biolabs Group Limited (NASDAQ:VRAX) Sees Large Decline in Short Interest

Virax Biolabs Group Limited (NASDAQ:VRAX) was the recipient of a significant drop in short interest in September. As of September 15th, there was short interest totaling 139,500 shares, a drop of 60.2% from the August 31st total of 350,900 shares. Based on an average daily volume of 583,600 shares, the short-interest ratio is currently 0.2 days. Approximately 3.6% of the company’s stock are short sold. Approximately 3.6% of the company’s stock are short sold. Based on an average daily volume of 583,600 shares, the short-interest ratio is currently 0.2 days.

Virax Biolabs Group Stock Performance

Virax Biolabs Group stock opened at $0.61 on Friday. The business has a fifty day moving average of $0.70 and a two-hundred day moving average of $0.89. Virax Biolabs Group has a twelve month low of $0.52 and a twelve month high of $3.62.

Virax Biolabs Group Company Profile

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.